Is Healthcare Losing the Status of Safe Haven? ETFs in Focus
Healthcare stocks face new risks under Trump, despite their usual defensive reputation.
XLV Vs. VHT: I Prefer XLV For Its Better Downturn Resilience
The Healthcare Sector, represented by XLV and VHT ETFs, offers a defensive investment option amid current market volatility and potential recession risks. Between these two funds, I prefer XLV even better. XLV has shown better performance in past market downturns - compared to both VHT and SP500 - with smaller worst-year losses and also worse drawdowns.
XLV: My Method For Navigating These Pullbacks
The Health Care Select Sector SPDR® Fund ETF is a highly representative ETF with $38.42 billion in AUM, a competitive expense ratio of 0.09%, and a dividend yield of 1.48%. Despite a 7% price drop since December, healthcare sector EPS expectations remain strong. XLV's forward P/E does not appear to show values significantly outside the historical distribution averages of the past 10 and 30 years.
Final Trade: FWONK, XLV, MSFT, PEP
The final trades of the day with CNBC's Melissa Lee and the Fast Money traders.
Stock Market Rotation: To Healthcare (XLV), Then Biotechnology (IBB)
Here are some of the recent references I have made about Biotechnology Sector (IBB) and the potential for a rally. Incidentally, Moderna (MRNA) is so oversold on a monthly timeframe, it should be on your radar.
Should You Invest in the Health Care Select Sector SPDR ETF (XLV)?
Launched on 12/16/1998, the Health Care Select Sector SPDR ETF (XLV) is a passively managed exchange traded fund designed to provide a broad exposure to the Healthcare - Broad segment of the equity market.
XLV: With Relative Strength In January And Compelling Valuation, Health Care Earnings On Tap
I maintain a buy rating on the Health Care sector, highlighting XLV as the second-best performing S&P 500 sector YTD with broad-based gains. Global fund managers have increased allocations to Health Care, signaling renewed optimism and a healthier sector outlook since my Q3 2024 analysis. XLV offers compelling valuation at 16.5x earnings with a PEG ratio of 1.5x, strong dividend growth, and a diversified portfolio leaning towards large-cap value.
XLV: Buy Diversity And Growth
XLV offers a rare combination of stability and growth potential through its diverse investments in the healthcare sector, justifying a buy rating. The fund's broad exposure across various healthcare sub-sectors and market capitalizations ensures low-risk concentration and a stable portfolio. Economic and demographic factors, including technological advancements and an aging population, are key growth catalysts for the healthcare sector.
Final Trade: XLV, DEO, OIH & BTC
The final trades of the day with CNBC's Melissa Lee and the Fast Money traders.
The M&A 'animal spirits' would be a tailwind for the healthcare sector, says JPMorgan's Meera Pandit
Meera Pandit, JPMorgan Asset Management global market strategist, joins 'Closing Bell' to discuss the road ahead for markets and which sectors will be the winners and losers in 2025.
Tema ETFs CIO says health care innovation to continue next year
Yuri Khodjamirian, CIO at Tema ETFs, discusses the outlook for the health care sector in 2025.
Investing in healthcare innovation will be a powerful driver of returns: Principal Asset's Maris
George Maris, Principal Asset Management CIO, joins 'Money Movers' to discuss why Maris likes certain parts of the healthcare space, if the overall market feels euphoric, and much more.
